Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Alfred L. Garfall(University of Pennsylvania), Amrita Krishnan(City of Hope), Laura Rosiñol(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Jesús F. San Miguel(Clinica Universidad de Navarra), María‐Victoria Mateos(Hospital Clínico San Carlos), Niels W.C.J. van de Donk(Oncode Institute), Manisha Bhutani(Carolinas Healthcare System), Ajai Chari(University of California, San Francisco), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Albert Oriol Rocafiguera(Institut Català d'Oncologia), Lixia Pei(Janssen (United States)), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Hareth Nahi(Karolinska University Hospital), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 60
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k